Clinical significance of B-type natriuretic peptide in the assessment of untreated hypertension

Circulation Journal

Volumn 72, Issue 5, 2008, Pages 770-777

  Seki, Shingo ^a   Tsurusaki, Tetsuji ^a   Kasai, Tokuo ^a   Taniguchi, Ikuo ^a   Mochizuki, Seibu ^a   Yoshimura, Michihiro ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

B type natriuretic peptide; Diastolic dysfunction; Hypertension; Hypertrophy; Pulse pressure

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CREATININE; HEMOGLOBIN; RENIN;

A WAVE; ADULT; ARTICLE; BODY MASS; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DECELERATION; DIASTOLIC DYSFUNCTION; DISEASE SEVERITY; ELECTROCARDIOGRAPHY; FEMALE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MULTIPLE REGRESSION; PARAMETER; PROTEIN BLOOD LEVEL; PULSE PRESSURE; STATISTICAL SIGNIFICANCE; THORAX RADIOGRAPHY;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD PRESSURE; CARDIOMEGALY; DIASTOLE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; PREVALENCE; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX;

EID: 44249084233     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.72.770     Document Type: Article

References (30)

1. Lewington S, Clarke R, Qizilbash N, Pelo R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality. Lancet 2002;360: 1903-1913.
2. Eyre H, Kahn R, Robertson RM. Preventing cancer, cardiovascular disease, and diabetes: A common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. Circulation 2004; 109: 3244-3255.
3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee of Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003; 289: 2560-2572.
4. Japanese Society of Hypertension. Guidelines for the Management of Hypertension (JSH). Hypertens Res 2006; 29(Suppl): S1-S106.
5. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105-1187.
6. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90: 195-203.
7. Tsutamoto T, Wada A, Maeda K. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96: 509-516.
8. Latini R. Masson S, de Angelis N, Biol D, Anand I. Role of brain natriuretic peptide in the diagnosis and management of heart failure: Current concepts. J Card Fail 2002; 8: 288-299.
9. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003; 107: 1231-1233.
10. Hirata Y, Matsumoto A, Aoyagi T, Yamaoki K, Komuro I, Suzuki T, et al. Measurement of plasma brain natriuretic peptide level as a guide for cardiac overload. Cardiovasc Res 2001; 51: 585-591.
11. Suzuki M, Hamada M, Yamamoto K, Kazatani Y, Hiwada K. Brain natriuretic peptide as a risk marker for incident hypertensive cardiovascular events. Hypertens Res 2002; 25: 669-676.
12. Nakamura M, Tanaka F, Yonezawa S, Satou K, Nagano M, Hiramori K. The limited value of plasma B-type natriuretic peptide for screening for left ventricular hypertrophy among hypertensive patients. Am J Hypertens 2003; 16: 1025-1029.
13. Uusimaa P, Tokola H, Ylitalo A, Vuolteenaho O, Ruskoaho H, Risteli J, et al. Plasma B-type netriuretic peptide reflects left ventricular hypertrophy and diastolic function in hypertension. Int J Cardiol 2004; 97: 251-256.
14. Kanda H, Kita Y, Okamura T, Kadowaki T, Yoshida Y, Ueshima H. What factors are associated with high plasma B-type natriuretic peptide levels in a general Japanese population? J Hum Hypertens 2005; 19: 165-172.
15. Kitzman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG, Marburger CT, et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002; 288: 2144-2150.
16. Mottram PM, Leano R, Marwick TH. Usefulness of B-type natriuretic peptide in hypertensive patients with exertional dyspnea and normal ieft ventricular ejection fraction and correlation with new echocardiographic indexes of systolic and diastolic function. Am J Cardiol 2003; 92: 1434-1438.
17. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, et al. Plasma natriuretic peptides levels and the risk of cardiovascular events and death. New Engl J Med 2004; 350: 655-663.
18. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977; 55: 613-618.
19. Niinuma H, Nakamura M, Hiramori K. Plasma B-type natriuretic peptide measurement in a multiphasic health screening program. Cardiology 1998; 90: 89-94.
20. Wei T, Zeng C, Chen L, Chen Q, Zhao R, Lu G, et al. Bedside tests of B-type natriuretic peptide in the diagnosis of left ventricular diastolic dysfunction in hypertensive patients. Eur J Heart Fail 2005; 7: 75-79.
21. Takagi S, Sakuragi S, Baba T, Takaki H, Aihara N, Yasumura Y, et al. Predictors of left ventricular remodeling in patients with acute myocardial infarction participating in cardiac rehabilitation: Brain natriuretic peptide and anterior infarction. Circ J 2004; 68: 214-219.
22. Ogawa K, Oida A, Sugimura H, Kaneko N, Nogi N, Hasumi M, et al. Clinical significance of blood brain natriuretic peptide level measurement in the detection of heart disease in untreated outpatients: Comparison of electrocardiography, chest radiography and echocardiography. Circ J 2002; 66: 122-126.
23. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, et al. Biochemical detection of left ventricular systolic dysfunction. Lancet 1998; 351: 9-13.
24. Ogino K, Ogura K, Kinugawa T, Osaki S, Kato M, Furuse Y. Neuro-humoral profiles in patients with hypertrophic cardiomyopathy: Differences to hypertensive left ventricular hypertrophy. Circ J 2004; 68: 444-450.
25. Davis M, Espiner E, Richards G, Billings J, Town I, Neill A, et al. Plasma brain natriureitic peptide in assessment of acute dyspnoea. Lancet 1994; 343: 440-444.
26. Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra R, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: Comparison with Doppler velocity recordings. Circulation 2002; 105: 595-601.
27. Kai H, Kuwahara F, Tokuda K, Tmaizumi T. Diastolic dysfunction in hypertensive hearts: Roles of perivascular inflammation and reactive myocardial fibrosis. Hypertens Res 2005; 28: 483-490.
28. Nishikimi T, Yoshihara F, Morimoto A. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 1996; 28: 22-30.
29. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PWF, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004; 109: 594-600.
30. Tshikawa C, Tsutamoto T, Fujii M, Sakai H, Tanaka T, Horie M. Prediction of mortality by high-sensitivity C-reactive protein and brain natriuretic peptide in patients with dilated cardiomyopathy. Circ J 2006; 70: 857-863.